C I Civin
Overview
Explore the profile of C I Civin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
137
Citations
2620
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhan T, Cao C, Li L, Gu N, Civin C, Zhan X
Leukemia
. 2016 Mar;
30(6):1327-34.
PMID: 26965284
Missing in metastasis (MIM) is abundantly expressed in hematopoietic cells. Here we characterized the impact of MIM deficiency on murine bone marrow (BM) cells. Although MIM(-/-) cells proliferated similarly to...
2.
Yu D, Zhan X, Zhao X, Williams M, Carey G, Smith E, et al.
Oncogene
. 2011 Nov;
31(30):3561-8.
PMID: 22081072
Missing in metastasis (MIM) is a member of newly emerged inverse Bin-Amphiphysin-Rvs (BAR) domain protein family and a putative metastasis suppressor. Although reduced MIM expression has been associated with bladder,...
3.
Morisot S, Wayne A, Bohana-Kashtan O, Kaplan I, Gocke C, Hildreth R, et al.
Leukemia
. 2010 Aug;
24(11):1859-66.
PMID: 20739953
In order to develop a xenograft model to determine the efficacy of new therapies against primary human precursor-B acute lymphoblastic leukemia (ALL) stem cells (LSCs), we used the highly immunodeficient...
4.
Zhang L, DCosta J, Kummalue T, Civin C, Friedman A
Oncogene
. 2006 Jun;
25(55):7289-96.
PMID: 16767164
In the core binding factor (CBF)beta-smooth muscle myosin heavy chain (SMMHC) acute myeloid leukemia (AML) oncoprotein, CBFbeta lies N-terminal to the alpha-helical rod domain of SMMHC. Deletion of the SMMHC...
5.
DCosta J, Chaudhuri S, Civin C, Friedman A
Leukemia
. 2005 Apr;
19(6):921-9.
PMID: 15815715
CBFbeta-SMMHC is expressed in 8% of acute myeloid leukemias and inhibits AML1/RUNX1. In this study, murine marrow or human CD34(+) cells were transduced with retroviral or lentiviral vectors expressing CBFbeta-SMMHC...
6.
Lewis L, Amin S, Civin C, Lietman P
Hum Exp Toxicol
. 2004 Jun;
23(4):173-85.
PMID: 15171568
Haematopoietic suppression is one of the dose-limiting side effects of chronic zidovudine (AZT) therapy. We tested the hypothesis that AZT would reduce mitochondrial DNA (mtDNA) content in haematopoietic progenitors causing...
7.
Lumkul R, Gorin N, Malehorn M, Hoehn G, Zheng R, Baldwin B, et al.
Leukemia
. 2002 Aug;
16(9):1818-26.
PMID: 12200698
Most cases of human acute myeloid leukemia (AML) engraft in irradiated non-obese diabetic/severe combined immunodeficient (NOD/SCID) mice. Intravenous transfer of as few as 10(5) human AML cells resulted in engraftment....
8.
Loeb D, Bowers D, Civin C, Friedman A
Med Pediatr Oncol
. 2001 Sep;
37(4):365-71.
PMID: 11568900
Background: Timed sequential chemotherapy and high-dose cytarabine (cytosine arabinoside, Ara-C; HDAC) are both effective treatments for acute myeloid leukemia (AML). We review our institutional experience with timed sequential induction chemotherapy...
9.
10.
Tse K, Novelli E, Civin C, Bohmer F, Small D
Leukemia
. 2001 Jul;
15(7):1001-10.
PMID: 11455967
FLT3 is a member of the type III receptor tyrosine kinase (RTK) family. These receptors all contain an intrinsic tyrosine kinase domain that is critical to signaling. Aberrant expression of...